Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

In the LEAP-002 study, Merck hoped to show that combining Keytruda with Lenvima would improve outcomes over two years' follow-up in patients with unresectable HCC. However, the duo was unable to ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

Keytruda might be prescribed by itself or with lenvatinib (Lenvima) in this case. TNBC with PD-L1 that’s recurring but can’t be removed by surgery, or is spreading from the breast to other ...

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business. But Merck's vaccine that prevents cancer from HPV ...

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat resectable non-small cell ...

Merck’s (NYSE:MRK) blockbuster cancer therapy Keytruda (pembrolizumab) has been cleared by the European Commission to treat two new indications in gynecologic cancers. The first approval is for ...